Comparison of treatment outcome between living donor liver transplantation and sorafenib for patients with hepatocellular carcinoma beyond the Milan criteria
Metrics: PDF 1071 views | HTML 1415 views | ?
Yuri Cho1,3, Jeong-Hoon Lee1, Dong Hyeon Lee1,4, Eun Ju Cho1, Su Jong Yu1, Nam-Joon Yi2, Kwang-Woong Lee2, Yoon Jun Kim1, Jung-Hwan Yoon1 and Kyung-Suk Suh2
1Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea
2Department of Surgery, Seoul National University College of Medicine, Seoul, Republic of Korea
3Department of Internal Medicine, CHA Gangnam Medical Center, CHA University, Seoul, Republic of Korea
4Department of Internal Medicine, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul, Republic of Korea
Jeong-Hoon Lee, email: email@example.com
Keywords: hepatocellular carcinoma, living donor liver transplantation, sorafenib, MoRAL score, survival
Received: March 29, 2017 Accepted: April 26, 2017 Published: May 10, 2017
For patients with advanced hepatocellular carcinoma (HCC), sorafenib is the only systemic treatment recommended by international guidelines. We recently reported that HCC patients with a low MoRAL (model to predict tumor recurrence after LDLT) score (≤ 314.8) have excellent treatment outcomes after living-donor liver transplantation (LDLT), even though they are beyond the Milan criteria. In the present study, we investigated whether LDLT offers a better treatment outcome than sorafenib for patients with HCC beyond the Milan criteria according to the MoRAL score. A retrospective cohort study of 325 consecutive patients who were treated with either LDLT (n = 122) or sorafenib (n = 203) for HCC beyond the Milan criteria from 2005 to 2014 at a tertiary hospital was performed. The primary and secondary endpoints were overall survival (OS) and time-to-progression. When baseline characteristics were balanced using inverse probability weighting, OS was significantly longer in the LDLT group than in the sorafenib group (5-year OS rate, 71.9% vs. 4.9%; HR=0.1; P < 0.001). The LDLT group exhibited a significantly lower risk of tumor progression (5-year recurrence rate, 34.7% vs. 96%; HR=0.14; P < 0.001) than the sorafenib group. The increase in OS with LDLT was predominantly among patients with a low MoRAL score (5-year OS rate, 81.1% vs. 5.8%; HR=0.06; P < 0.001) compared with those with a high MoRAL score (5-year OS rate, 28.3% vs. 4.3%; HR = 0.42; P = 0.047). Patients with a low MoRAL score and without extrahepatic metastasis or hepatic vein invasion might be good candidates for LDLT instead of sorafenib treatment if there is a willing living related donor.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.